Puma Biotechnology, Inc.

NasdaqGS:PBYI Stock Report

Market Cap: US$146.3m

Puma Biotechnology Management

Management criteria checks 3/4

Puma Biotechnology's CEO is Alan Auerbach, appointed in Sep 2010, has a tenure of 14.33 years. total yearly compensation is $2.94M, comprised of 29.8% salary and 70.2% bonuses, including company stock and options. directly owns 14.15% of the company’s shares, worth $20.70M. The average tenure of the management team and the board of directors is 7 years and 8.2 years respectively.

Key information

Alan Auerbach

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage29.8%
CEO tenure14.3yrs
CEO ownership14.2%
Management average tenure7yrs
Board average tenure8.2yrs

Recent management updates

Recent updates

Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price

Jan 14
Insufficient Growth At Puma Biotechnology, Inc. (NASDAQ:PBYI) Hampers Share Price

Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward

Dec 16

Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Nov 14
Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest

Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Sep 07
Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?

Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

Aug 15
Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop

The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Jun 07
The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%

Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

Jun 05
Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today

We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

May 09
We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings

Puma Biotechnology: A Story In Flux Heading Into Mid-2024

May 05

Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

Apr 10
Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?

There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Mar 01
There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump

Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Dec 27
Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden

Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Sep 08
Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet

Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

Apr 17
Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%

We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Dec 14
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt

Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib

Sep 20

CEO Compensation Analysis

How has Alan Auerbach's remuneration changed compared to Puma Biotechnology's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

US$23m

Jun 30 2024n/an/a

US$9m

Mar 31 2024n/an/a

US$15m

Dec 31 2023US$3mUS$878k

US$22m

Sep 30 2023n/an/a

US$4m

Jun 30 2023n/an/a

-US$2m

Mar 31 2023n/an/a

US$5m

Dec 31 2022US$3mUS$852k

US$2k

Sep 30 2022n/an/a

US$10m

Jun 30 2022n/an/a

-US$34m

Mar 31 2022n/an/a

-US$49m

Dec 31 2021US$18mUS$827k

-US$29m

Sep 30 2021n/an/a

-US$48m

Jun 30 2021n/an/a

-US$35m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020US$4mUS$834k

-US$60m

Sep 30 2020n/an/a

-US$56m

Jun 30 2020n/an/a

-US$42m

Mar 31 2020n/an/a

-US$82m

Dec 31 2019US$4mUS$780k

-US$76m

Sep 30 2019n/an/a

-US$95m

Jun 30 2019n/an/a

-US$92m

Mar 31 2019n/an/a

-US$99m

Dec 31 2018US$6mUS$757k

-US$114m

Compensation vs Market: Alan's total compensation ($USD2.94M) is above average for companies of similar size in the US market ($USD645.26K).

Compensation vs Earnings: Alan's compensation has been consistent with company performance over the past year.

CEO

Alan Auerbach (54 yo)

14.3yrs

Tenure

US$2,944,748

Compensation

Mr. Alan H. Auerbach is the Founder of Puma Biotechnology, Inc. and has been its Executive Chairman since October 4, 2011 and serves as its Chief Executive Officer, President and Secretary since September...

Leadership Team

NamePositionTenureCompensationOwnership
Alan Auerbach
Founder14.3yrsUS$2.94m14.15%
$ 20.7m
Maximo Nougues
CFO & Principal Accounting Officer6.2yrsUS$1.23m0.27%
$ 389.3k
Douglas Hunt
Chief Regulatory Affairs7yrsUS$1.02m0.22%
$ 314.8k
Jeffrey Ludwig
Chief Commercial Officer4.8yrsUS$1.38m0.19%
$ 284.3k
Mariann Ohanesian
Senior Director of Investor Relations13.2yrsno datano data

7.0yrs

Average Tenure

56.5yo

Average Age

Experienced Management: PBYI's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Alan Auerbach
Founder13.3yrsUS$2.94m14.15%
$ 20.7m
Jay Moyes
Lead Independent Director12.8yrsUS$172.27k0.043%
$ 63.5k
Michael Miller
Independent Director6.9yrsUS$162.90k0.041%
$ 59.6k
Troy Wilson
Independent Director11.3yrsUS$172.27k0.0018%
$ 2.7k
Alessandra Cesano
Independent Director2.5yrsUS$152.27k0.055%
$ 80.5k
Adrian Senderowicz
Independent Director9.4yrsUS$164.77k0%
$ 0
Allison Dorval
Independent Director3.5yrsUS$154.77k0.067%
$ 98.3k
Brian Stuglik
Independent Director4.5yrsUS$161.65k0.10%
$ 146.2k

8.2yrs

Average Tenure

62yo

Average Age

Experienced Board: PBYI's board of directors are considered experienced (8.2 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 23:11
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Puma Biotechnology, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Huidong WangBarclays
Geoffrey MeachamBofA Global Research
Alethia YoungCantor Fitzgerald & Co.